Coeptis Therapeutics Plans To Pursue DVX201, Its Proprietary Allogeneic Stem Cell Expansion And Directed Differentiation Platform Of Unmodified Natural Killer Cell Therapy, As An Antiviral Treatment Addressing Various Respiratory Viral Infections
Benzinga Newsdesk - Feb 7, 2024, 7:40AM